BNOX (Bionomics) Debt-to-Equity : 0.02 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bionomics Debt-to-Equity?

Bionomics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.17 Mil. Bionomics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.09 Mil. Bionomics's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $17.07 Mil. Bionomics's debt to equity for the quarter that ended in Sep. 2024 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bionomics's Debt-to-Equity or its related term are showing as below:

BNOX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.46 Max: 1.27
Current: 0.02

During the past 13 years, the highest Debt-to-Equity Ratio of Bionomics was 1.27. The lowest was 0.01. And the median was 0.46.

BNOX's Debt-to-Equity is ranked better than
88.37% of 1023 companies
in the Biotechnology industry
Industry Median: 0.14 vs BNOX: 0.02

Bionomics Debt-to-Equity Historical Data

The historical data trend for Bionomics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionomics Debt-to-Equity Chart

Bionomics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Debt-to-Equity

Get a 7-Day Free Trial

0.97

0.02

0.01

0.02

Bionomics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															0.02	N/A	0.05	0.02	0.02

Competitive Comparison of Bionomics's Debt-to-Equity

For the Biotechnology subindustry, Bionomics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bionomics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bionomics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bionomics's Debt-to-Equity falls into.

Bionomics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bionomics's Debt to Equity Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.155	+	0.118)	/	17.49
	=	0.02

Bionomics's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.165	+	0.089)	/	17.07
	=	0.01

Bionomics (NAS:BNOX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Bionomics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bionomics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bionomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bionomics Ltd (NAS:BNOX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

B1N0:Germany B1N0:Germany

Address

200 Greenhill Road, Eastwood, SA, AUS, 5063

Website

https://www.bionomics.com.au

Bionomics Ltd is a clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company's reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.